These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29758406)

  • 1. Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET.
    Singh PK; Silakari O
    Bioorg Chem; 2018 Sep; 79():163-170. PubMed ID: 29758406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico guided development of imine-based inhibitors for resistance-deriving kinases.
    Kumar Singh P; Silakari O
    J Biomol Struct Dyn; 2019 Jul; 37(10):2593-2599. PubMed ID: 30047303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
    Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel EGFR (T790M)-cMET dual inhibitors: putative therapeutic agents for non-small-cell lung cancer.
    Singh PK; Silakari O
    Future Med Chem; 2017 Apr; 9(5):469-483. PubMed ID: 28362115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure based designing of triazolopyrimidone-based reversible inhibitors for kinases involved in NSCLC.
    Singh PK; Chaudhari D; Jain S; Silakari O
    Bioorg Med Chem Lett; 2019 Jul; 29(13):1565-1571. PubMed ID: 31078412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.
    Xu L; Kikuchi E; Xu C; Ebi H; Ercan D; Cheng KA; Padera R; Engelman JA; Jänne PA; Shapiro GI; Shimamura T; Wong KK
    Cancer Res; 2012 Jul; 72(13):3302-11. PubMed ID: 22552292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
    Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
    J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
    Liu Z; Wang L; Feng M; Yi Y; Zhang W; Liu W; Li L; Liu Z; Li Y; Ma X
    Bioorg Chem; 2018 Apr; 77():593-599. PubMed ID: 29482151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
    Li Y; Song Z; Jin Y; Tang Z; Kang J; Ma X
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27827863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
    Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of EGF Receptor Inhibitors That Are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design.
    Park H; Jung HY; Mah S; Hong S
    Angew Chem Int Ed Engl; 2017 Jun; 56(26):7634-7638. PubMed ID: 28493467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
    Günther M; Lategahn J; Juchum M; Döring E; Keul M; Engel J; Tumbrink HL; Rauh D; Laufer S
    J Med Chem; 2017 Jul; 60(13):5613-5637. PubMed ID: 28603991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.
    Juchum M; Günther M; Döring E; Sievers-Engler A; Lämmerhofer M; Laufer S
    J Med Chem; 2017 Jun; 60(11):4636-4656. PubMed ID: 28482151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors.
    Hao Y; Lyu J; Qu R; Sun D; Zhao Z; Chen Z; Ding J; Xie H; Xu Y; Li H
    Sci Rep; 2017 Jun; 7(1):3830. PubMed ID: 28630494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
    Planken S; Behenna DC; Nair SK; Johnson TO; Nagata A; Almaden C; Bailey S; Ballard TE; Bernier L; Cheng H; Cho-Schultz S; Dalvie D; Deal JG; Dinh DM; Edwards MP; Ferre RA; Gajiwala KS; Hemkens M; Kania RS; Kath JC; Matthews J; Murray BW; Niessen S; Orr ST; Pairish M; Sach NW; Shen H; Shi M; Solowiej J; Tran K; Tseng E; Vicini P; Wang Y; Weinrich SL; Zhou R; Zientek M; Liu L; Luo Y; Xin S; Zhang C; Lafontaine J
    J Med Chem; 2017 Apr; 60(7):3002-3019. PubMed ID: 28287730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations.
    Xiao Z; Zhou Z; Chu C; Zhang Q; Zhou L; Yang Z; Li X; Yu L; Zheng P; Xu S; Zhu W
    Eur J Med Chem; 2020 Oct; 203():112511. PubMed ID: 32679450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant.
    Fukuda T; Umeki T; Tokushima K; Xiang G; Yoshida Y; Ishibashi F; Oku Y; Nishiya N; Uehara Y; Iwao M
    Bioorg Med Chem; 2017 Dec; 25(24):6563-6580. PubMed ID: 29133033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dynamics and pharmacophore modelling studies of different subtype (ALK and EGFR (T790M)) inhibitors in NSCLC.
    Singh PK; Silakari O
    SAR QSAR Environ Res; 2017 Mar; 28(3):221-233. PubMed ID: 28290719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of selective degraders of EGFR
    Zhang X; Xu F; Tong L; Zhang T; Xie H; Lu X; Ren X; Ding K
    Eur J Med Chem; 2020 Apr; 192():112199. PubMed ID: 32171162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.